FREEMAN KEVIN D 4/A
4/A · GALECTIN THERAPEUTICS INC · Filed Jan 19, 2022
Insider Transaction Report
Form 4/AAmended
FREEMAN KEVIN D
Director
Transactions
- Purchase
Common Stock
2022-01-19$1.96/sh+5,000$9,806→ 55,000 total(indirect: By LLC)
Holdings
- 23,469
Common Stock
- 16,000(indirect: By IRA)
Common Stock
Footnotes (1)
- [F1]Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.